ATyr Pharma, a biotherapeutics company focused on a range of rare diseases, has attracted a $76m series E round from investors including healthcare services provider Sphera Global Healthcare.
The round was led by Sofinnova Ventures as well as an unnamed institutional investor in the biotechnology sector. T Rowe Price Associates, Federated Investors, Deerfield, Rock Springs Capital Management, EcoR1 Capital and two other unnamed investors also participated in the round alongside unnamed existing investors.
Founded in 2005, ATyr has raised at…
